JP2020528455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528455A5 JP2020528455A5 JP2020524723A JP2020524723A JP2020528455A5 JP 2020528455 A5 JP2020528455 A5 JP 2020528455A5 JP 2020524723 A JP2020524723 A JP 2020524723A JP 2020524723 A JP2020524723 A JP 2020524723A JP 2020528455 A5 JP2020528455 A5 JP 2020528455A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphocytes
- hprt
- deficient
- patient
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 26
- 210000004698 lymphocyte Anatomy 0.000 claims 23
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims 15
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims 13
- 230000002950 deficient Effects 0.000 claims 13
- 238000001802 infusion Methods 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 150000003212 purines Chemical class 0.000 claims 3
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 2
- 206010061819 Disease recurrence Diseases 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 108700010039 chimeric receptor Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000001400 myeloablative effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533707P | 2017-07-18 | 2017-07-18 | |
| US62/533,707 | 2017-07-18 | ||
| PCT/US2018/042630 WO2019018491A1 (en) | 2017-07-18 | 2018-07-18 | MODULAR SWITCH FOR SELECTING DONOR MODIFIED CELLS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528455A JP2020528455A (ja) | 2020-09-24 |
| JP2020528455A5 true JP2020528455A5 (OSRAM) | 2021-08-26 |
| JP7410856B2 JP7410856B2 (ja) | 2024-01-10 |
Family
ID=63104099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524723A Active JP7410856B2 (ja) | 2017-07-18 | 2018-07-18 | ドナー改変細胞の選択のための調節可能スイッチ |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10426798B2 (OSRAM) |
| EP (2) | EP4190339B1 (OSRAM) |
| JP (1) | JP7410856B2 (OSRAM) |
| KR (1) | KR20200125574A (OSRAM) |
| CN (1) | CN111343996A (OSRAM) |
| AU (1) | AU2018304222A1 (OSRAM) |
| BR (1) | BR112020001132A2 (OSRAM) |
| CA (1) | CA3070258A1 (OSRAM) |
| ES (2) | ES3036762T3 (OSRAM) |
| SG (1) | SG11202000428PA (OSRAM) |
| WO (1) | WO2019018491A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP4190339B1 (en) * | 2017-07-18 | 2025-07-02 | CSL Behring Gene Therapy, Inc. | A modulatable switch for selection of donor modified cells |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
| JP2022514954A (ja) * | 2018-12-23 | 2022-02-16 | シーエスエル・ベーリング・エルエルシー | キルスイッチを有するドナーｔ細胞 |
| JP2023531729A (ja) * | 2020-06-26 | 2023-07-25 | シーエスエル・ベーリング・エルエルシー | キルスイッチを有するドナーｔ細胞 |
| US20250154457A1 (en) * | 2021-03-04 | 2025-05-15 | City Of Hope | T-cells for anti-hiv car-t therapy and methods of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US922105A (en) | 1908-10-14 | 1909-05-18 | Axel E Anderson | Hoisting apparatus. |
| WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| US5965126A (en) | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| WO1997043900A1 (en) | 1996-05-24 | 1997-11-27 | The President And Fellows Of Harvard College | In vivo selection |
| AU7605796A (en) | 1996-11-04 | 1998-05-29 | Saint Jude Children's Research Hospital | (in vivo) selection of primitive hematopoietic cells |
| JP2001523645A (ja) | 1997-11-14 | 2001-11-27 | ザ・ゼネラル・ホスピタル・コーポレイション | 血液学的疾患の処置 |
| US7094885B2 (en) | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
| US20030032003A1 (en) | 2000-02-02 | 2003-02-13 | Schiestl Robert H. | In vivo selection |
| AU2002219828A1 (en) | 2000-11-14 | 2002-05-27 | The General Hospital Corporation | Blockade of T cell migration into epithelial GVHD target tissues |
| US7037900B2 (en) | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
| SG178885A1 (en) * | 2009-08-24 | 2012-04-27 | Baylor College Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| TR201808037T4 (tr) * | 2011-04-20 | 2018-06-21 | Univ California | Tek bir döngüde kombine koşullandırma ve kemo seçimine yönelik yöntem. |
| CA3099582A1 (en) * | 2011-10-27 | 2013-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
| US20150245364A1 (en) | 2012-02-16 | 2015-08-27 | Hewlett-Packard Development Company, L.P. | Radio resource management |
| JP6976058B2 (ja) * | 2013-11-22 | 2021-12-01 | セレクティスCellectis | 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法 |
| JP2018522907A (ja) * | 2015-08-11 | 2018-08-16 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞 |
| WO2017126987A1 (ru) * | 2016-01-18 | 2017-07-27 | Анатолий Викторович ЗАЗУЛЯ | Эритроциты для направленного транспорта лекарственного средства |
| CN108495640B (zh) | 2016-02-19 | 2022-11-04 | 加利福尼亚大学董事会 | 短发夹rna(shrna734)及其用于阳性选择和消除遗传修饰的细胞的用途 |
| US20180140606A1 (en) * | 2016-11-18 | 2018-05-24 | Calimmune, Inc. | In Vivo Chemoselection with Low Dose Thioguanine |
| EP4190339B1 (en) * | 2017-07-18 | 2025-07-02 | CSL Behring Gene Therapy, Inc. | A modulatable switch for selection of donor modified cells |
-
2018
- 2018-07-18 EP EP22216082.2A patent/EP4190339B1/en active Active
- 2018-07-18 SG SG11202000428PA patent/SG11202000428PA/en unknown
- 2018-07-18 JP JP2020524723A patent/JP7410856B2/ja active Active
- 2018-07-18 US US16/038,643 patent/US10426798B2/en active Active
- 2018-07-18 CN CN201880058795.8A patent/CN111343996A/zh active Pending
- 2018-07-18 ES ES22216082T patent/ES3036762T3/es active Active
- 2018-07-18 AU AU2018304222A patent/AU2018304222A1/en not_active Abandoned
- 2018-07-18 BR BR112020001132-0A patent/BR112020001132A2/pt not_active Application Discontinuation
- 2018-07-18 CA CA3070258A patent/CA3070258A1/en active Pending
- 2018-07-18 EP EP18750006.1A patent/EP3654994B1/en active Active
- 2018-07-18 WO PCT/US2018/042630 patent/WO2019018491A1/en not_active Ceased
- 2018-07-18 ES ES18750006T patent/ES2940681T3/es active Active
- 2018-07-18 KR KR1020207004622A patent/KR20200125574A/ko not_active Ceased
-
2019
- 2019-08-12 US US16/538,818 patent/US11213548B2/en active Active
-
2021
- 2021-11-24 US US17/534,513 patent/US20220072046A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528455A5 (OSRAM) | ||
| Knobler et al. | Extracorporeal photopheresis: past, present, and future | |
| US20200147084A1 (en) | Tec family kinase inhibitor adjuvant therapy | |
| US11369623B2 (en) | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor | |
| Tran et al. | Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation | |
| Lugtenburg et al. | First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBodyŪ-CD3ŨCD20) in B-Cell Non-Hodgkin Lymphomas | |
| Braun et al. | Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease | |
| Korets et al. | Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer | |
| Wang et al. | Radiation therapy regulates TCF-1 to maintain CD8+ T cell stemness and promotes anti-tumor immunotherapy | |
| DiNardo et al. | Treatment advances in posttransplant lymphoproliferative disease | |
| Ganta et al. | Chronic graft-versus-host disease presenting as eosinophilic fasciitis: therapeutic challenges and an additional case | |
| Hamadani et al. | Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| Beaudreuil et al. | New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation? | |
| JP2020527156A (ja) | 自己免疫性神経筋疾患を処置するためのクラドリビンの使用 | |
| Felchle et al. | Influence of intestinal microbial metabolites on the abscopal effect after radiation therapy combined with immune checkpoint inhibitors | |
| US20190231757A1 (en) | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents | |
| Gigli et al. | Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: A case report | |
| WO2017114215A1 (zh) | 重组人钙调磷酸酶b亚基的应用 | |
| ORALLY | Session I: Molecular Oncology, Cytokines, New Treatment Modalities, Clinical Pharmacology | |
| Czaja | Therapy of autoimmune diseases-state of the art | |
| Palshof et al. | An open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients with solid tumors | |
| Bonavida et al. | FECAL MICROBIOTA TRANSPLANTATION IN MELANOMA: MECHANISMS-MEDIATED ENHANCEMENT OF ANTI-TUMOR IMMUNOTHERAPY | |
| Li et al. | PROLONGED ALLOGRAFT SURVIVAL IN PRESENSITIZED RATS AFTER A HIGH ACTIVITY Y-CVF THERAPY. | |
| Rule | EVEROLIMUS IN RELAPSED HODGKIN LYMPHOMA, SOMETHING EXCITING OR A CASE OF CAVEAT mTOR? |